Compare · GNPX vs SRPT
GNPX vs SRPT
Side-by-side comparison of Genprex Inc. (GNPX) and Sarepta Therapeutics Inc. (SRPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNPX and SRPT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SRPT is the larger of the two at $1.52B, about 681.7x GNPX ($2.2M).
- GNPX has been more active in the news (9 items in the past 4 weeks vs 8 for SRPT).
- SRPT has more recent analyst coverage (25 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- Sarepta Therapeutics Inc.
- Price
- -
- -
- Market cap
- $2.2M
- $1.52B
- 1M return
- -
- -23.76%
- 1Y return
- -
- -14.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 8
- Recent ratings
- 0
- 25
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Latest GNPX
- Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 10-Q filed by Genprex Inc.
- Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 8-K filed by Genprex Inc.
- Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
- SEC Form 8-K filed by Genprex Inc.
Latest SRPT
- SEC Form 13F-HR filed by Sarepta Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics upgraded by Deutsche Bank with a new price target
- Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
- SEC Form 10-Q filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting